Trial reaches objectives of significantly reducing allergy symptom scores and anti-allergy medication use during ragweed pollen season.
http://www.marketwatch.com/story/greerr-reports-positive-findings-from-large-phase-iii-clinical-trial-evaluating-sublingual-immunotherapy-for-ragweed-allergies-2012-06-12
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment